Key Details
Price
$0.16Annual ROE
-278.72%Beta
-0.38Events Calendar
Next earnings date:
Mar 07, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 07, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Feb 25, 2021Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Viracta Therapeutics (NASDAQ: VIRX ) stock is heading higher on Wednesday after the clinical-stage precision oncology company released its Q2 earnings report. The first bit of news boosting VIRX stock higher is its diluted earnings per share of -25 cents.
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity and generally well-tolerated safety profile -
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced that Michael Faerm has been appointed as the new Chief Financial Officer and was granted a non-qualified stock option to purchase 500,000 shares of common stock. The Board of Directors also approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. The options vest over four years, with 25% vesting on May 13, 2025, and the remaining 75% vesting in equal monthly increments over the next 36 months, contingent on continuous service to Viracta. The exercise price for each option is $0.804 per share, based on the closing price on May 14, 2024.
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET.
FAQ
- What is the primary business of Viracta Therapeutics?
- What is the ticker symbol for Viracta Therapeutics?
- Does Viracta Therapeutics pay dividends?
- What sector is Viracta Therapeutics in?
- What industry is Viracta Therapeutics in?
- What country is Viracta Therapeutics based in?
- When did Viracta Therapeutics go public?
- Is Viracta Therapeutics in the S&P 500?
- Is Viracta Therapeutics in the NASDAQ 100?
- Is Viracta Therapeutics in the Dow Jones?
- When was Viracta Therapeutics's last earnings report?
- When does Viracta Therapeutics report earnings?
- Should I buy Viracta Therapeutics stock now?